Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study

Journal for ImmunoTherapy of Cancer, Journal Year: 2025, Volume and Issue: 13(1), P. e009415 - e009415

Published: Jan. 1, 2025

Background Immune checkpoint inhibitors (ICIs) in combination with antiangiogenic drugs have shown promising outcomes the third-line and subsequent treatments of patients microsatellite stable metastatic colorectal cancer (MSS-mCRC). Radiotherapy (RT) may enhance antitumor effect immunotherapy. However, RT exposure on receiving ICIs targeted therapy remains unclear. This study aimed to investigate association between clinical responses fruquintinib (a highly selective tyrosine kinase inhibitor vascular endothelial growth factor receptor) plus sintilimab (an anti-programmed death 1 antibody; F&S) previously treated MSS-mCRC explore predictive biomarkers. Methods In this prospective observational study, mCRC F&S as or treatment were enrolled. Eligible divided into cohort (RTC) non-RT (NRTC) according their history. The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control (DCR), progression-free survival (PFS), overall (OS), safety. Pretreatment fecal serum samples collected for microbiome analysis, metabolome immune signatures identify biomarkers treatment. Results A total 55 included, which 25 RTC 30 NRTC. Better ORR (28.0% vs 6.7%, p=0.048), DCR (80.0% 36.7%, p=0.002), median PFS (6.2 2.7 months, p<0.001), OS (14.8 5.9 p=0.019) noted than those enrichment Lactobacillus , Bifidobacterium PC(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z)) significantly predicted better PFS, whereas guanosine interleukin-10 predominated NRTC negatively correlated OS. Conclusions Patients benefited from MSS-mCRC. Gut microbiota, metabolites, cytokines help predict mCRC, be helpful decision-making. Trial registration number ClinicalTrials.gov identifier: NCT05635149 .

Language: Английский

Letter to the editor: effects of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer—a prospective observation study

Journal for ImmunoTherapy of Cancer, Journal Year: 2025, Volume and Issue: 13(2), P. e011678 - e011678

Published: Feb. 1, 2025

As an oncology physician, I appreciate the prospective study conducted by Cheng and colleagues, which investigates survival benefits of advanced microsatellite stable (MSS) colorectal cancer patients treated with radiotherapy, fruquintinib, sintilimab.[1][1] This trial compared effects

Language: Английский

Decoding colorectal cancer targeted therapy: a bibliometric journey of the last decade (2015–2024)

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: April 1, 2025

Language: Английский